JPM vs MFIN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MFIN presents a classic deep-value opportunity, trading significantly below its Graham Number ($26.86) and Intrinsic Value ($52.22). While the Piotroski F-Score of 4/9 indicates only stable financial health and the Debt/Equity ratio is high at 4.73, the company demonstrates strong profitability and a consistent track record of earnings beats. The extreme disconnect between the current price ($9.41) and fundamental value metrics suggests a significant margin of safety, provided the high leverage is managed. Technicals remain bearish, but the fundamental growth and valuation profile are compelling.
Compare Another Pair
Related Comparisons
JPM vs MFIN: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Medallion Financial Corp. (MFIN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.